Search Results

There are 4166 results for: content related to: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

  1. You have free access to this content
    Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer

    Intervention Review

    The Cochrane Library

    Zu-Yao Yang, Li Liu, Chen Mao, Xin-Yin Wu, Ya-Fang Huang, Xue-Feng Hu and Jin-Ling Tang

    Published Online : 17 NOV 2014, DOI: 10.1002/14651858.CD009948.pub2

  2. You have free access to this content
    Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody–drug conjugates by cholesterol sequestration

    International Journal of Cancer

    Volume 136, Issue 1, 1 January 2015, Pages: 182–194, Yang Chen, Guanghua Liu, Lifang Guo, Hui Wang, Yan Fu and Yongzhang Luo

    Version of Record online : 14 MAY 2014, DOI: 10.1002/ijc.28950

  3. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer

    Intervention Review

    The Cochrane Library

    David Lok Hang Chan, Eva Segelov, Rachel SH Wong, Annabel Smith, Rebecca A Herbertson, Bob T. Li, Niall Tebbutt, Timothy Price and Nick Pavlakis

    Published Online : 27 JUN 2017, DOI: 10.1002/14651858.CD007047.pub2

  4. You have free access to this content
    Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model

    International Journal of Cancer

    Volume 129, Issue 4, 15 August 2011, Pages: 870–878, Bianca A.W. Hoeben, Janneke D.M. Molkenboer-Kuenen, Wim J.G. Oyen, Wenny J.M. Peeters, Johannes H.A.M. Kaanders, Johan Bussink and Otto C. Boerman

    Version of Record online : 1 DEC 2010, DOI: 10.1002/ijc.25727

  5. You have full text access to this Open Access content
    Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III

    Cancer Science

    Volume 99, Issue 10, October 2008, Pages: 2062–2069, Junya Fukai, Kazuto Nishio, Toru Itakura and Fumiaki Koizumi

    Version of Record online : 3 OCT 2008, DOI: 10.1111/j.1349-7006.2008.00945.x

  6. Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab

    The Journal of Clinical Pharmacology

    Volume 52, Issue 2, February 2012, Pages: 128–155, Dr Benoit You and Dr Eric X. Chen

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010395940

  7. You have full text access to this OnlineOpen article
    A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils

    Cancer Medicine

    Volume 5, Issue 6, June 2016, Pages: 1004–1012, Takuya Iwamoto, Akiharu Okamoto, Hajime Ishinaga, Kasumi Shimizu, Alberto A. Gayle, Naoya Arai, Kazuhiko Takeuchi and Masahiro Okuda

    Version of Record online : 16 FEB 2016, DOI: 10.1002/cam4.658

  8. You have full text access to this OnlineOpen article
    A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck

    Cancer Medicine

    Volume 3, Issue 6, December 2014, Pages: 1493–1501, Douglas Adkins, Jessica Ley, Farrokh Dehdashti, Marilyn J. Siegel, Tanya M. Wildes, Loren Michel, Kathryn Trinkaus and Barry A. Siegel

    Version of Record online : 1 AUG 2014, DOI: 10.1002/cam4.294

  9. You have full text access to this OnlineOpen article
    Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit

    Cancer Medicine

    Volume 4, Issue 1, January 2015, Pages: 65–74, Uma Raju, David P. Molkentine, David R. Valdecanas, Amit Deorukhkar, Kathryn A. Mason, Thomas A. Buchholz, Raymond E. Meyn, Kie-Kian Ang and Heath Skinner

    Version of Record online : 29 OCT 2014, DOI: 10.1002/cam4.345

  10. You have full text access to this Open Access content
    Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

    Cancer Science

    Volume 99, Issue 7, July 2008, Pages: 1471–1478, Masayasu Hara, Hayao Nakanishi, Kunio Tsujimura, Makoto Matsui, Yasushi Yatabe, Tadao Manabe and Masae Tatematsu

    Version of Record online : 16 APR 2008, DOI: 10.1111/j.1349-7006.2008.00821.x

  11. 90Y/177Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation

    Journal of Labelled Compounds and Radiopharmaceuticals

    Volume 59, Issue 9, July 2016, Pages: 354–363, Rubel Chakravarty, Sudipta Chakraborty, Haladhar Dev Sarma, K. V. Vimalnath Nair, Ardhi Rajeswari and Ashutosh Dash

    Version of Record online : 5 JUN 2016, DOI: 10.1002/jlcr.3413

  12. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice

    Contrast Media & Molecular Imaging

    Volume 8, Issue 5, September/October 2013, Pages: 402–408, Linda Karmani, Daniel Labar, Vanessa Valembois, Virginie Bouchat, Praveen Ganesh Nagaswaran, Anne Bol, Jacques Gillart, Philippe Levêque, Caroline Bouzin, Davide Bonifazi, Carine Michiels, Olivier Feron, Vincent Grégoire, Stéphane Lucas, Thierry Vander Borght and Bernard Gallez

    Version of Record online : 6 JUN 2013, DOI: 10.1002/cmmi.1539

  13. Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

    The Journal of Clinical Pharmacology

    Volume 48, Issue 3, March 2008, Pages: 267–278, Dr Nathanae L. Dirks, Dr Arno Nolting, Dr Andreas Kovar and Dr Bernd Meibohm

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007313393

  14. You have full text access to this Open Access content
    Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography

    Cancer Science

    Volume 103, Issue 3, March 2012, Pages: 600–605, Arifudin Achmad, Hirofumi Hanaoka, Hiroki Yoshioka, Shinji Yamamoto, Hideyuki Tominaga, Takuya Araki, Yasuhiro Ohshima, Noboru Oriuchi and Keigo Endo

    Version of Record online : 23 DEC 2011, DOI: 10.1111/j.1349-7006.2011.02166.x

  15. The role of cetuximab as first-line treatment of colorectal liver metastases

    HPB

    Volume 15, Issue 1, January 2013, Pages: 11–17, Claire Jones, Mark A. Taylor and Billy McWilliams

    Version of Record online : 17 OCT 2012, DOI: 10.1111/j.1477-2574.2012.00591.x

  16. You have free access to this content
    Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation

    Cytometry Part A

    Volume 81A, Issue 10, October 2012, Pages: 865–873, M. Ingargiola, C. Dittfeld, R. Runge, M. Zenker, J.-M. Heldt, J. Steinbach, N. Cordes, M. Baumann, J. Kotzerke and L. A. Kunz-Schughart

    Version of Record online : 28 AUG 2012, DOI: 10.1002/cyto.a.22110

  17. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

    British Journal of Clinical Pharmacology

    Volume 83, Issue 3, March 2017, Pages: 623–631, Benoît Dupont, Delphine Mariotte, Audrey E. Dugué, Bénédicte Clarisse, Jean-Michel Grellard, Emmanuel Babin, Bruno Chauffert, Stéphanie Dakpé, Cristian Moldovan, Karine Bouhier-Leporrier, Jean-Marie Reimund, Frederic Di Fiore, Sylvie Zanetta, Audrey Mailliez, Pascal Do, Annie Peytier, Marie-Pierre Galais, Carmen Florescu, Roland Schott, Brigitte Le Mauff and Radj Gervais

    Version of Record online : 24 OCT 2016, DOI: 10.1111/bcp.13140

  18. Inhibition of epithelial–mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer

    Head & Neck

    Volume 39, Issue 3, March 2017, Pages: 476–485, Yoshifumi Matsumoto, Hiroyuki Sakurai, Yasunao Kogashiwa, Toru Kimura, Yuma Matsumoto, Takashi Shionome, Masatake Asano, Koichiro Saito and Naoyuki Kohno

    Version of Record online : 23 NOV 2016, DOI: 10.1002/hed.24626

  19. You have free access to this content
    KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells

    International Journal of Cancer

    Volume 134, Issue 9, 01 May 2014, Pages: 2146–2155, Yusuke Nakadate, Yasuo Kodera, Yuka Kitamura, Senji Shirasawa, Taro Tachibana, Tomohide Tamura and Fumiaki Koizumi

    Version of Record online : 4 NOV 2013, DOI: 10.1002/ijc.28550

  20. Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model

    Small

    Volume 9, Issue 24, December 20, 2013, Pages: 4221–4236, Nour Karra, Taher Nassar, Alina Nemirovski Ripin, Ouri Schwob, Jürgen Borlak and Simon Benita

    Version of Record online : 21 JUL 2013, DOI: 10.1002/smll.201301417